UroGen Weighs ENVISION Success And Expanded Loan In Bladder Cancer Push [Yahoo! Finance]
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.urogen.com
Company Research
Source: Yahoo! Finance
UroGen Pharma (NasdaqGM:URGN) reported new Phase 3 ENVISION trial analyses for ZUSDURI in recurrent low grade intermediate risk non muscle invasive bladder cancer, showing strong efficacy across risk groups. The company highlighted high complete response rates and durable benefit in a patient population with limited treatment options. UroGen also secured an expanded US$250 million non dilutive term loan with a fixed interest rate and no financial covenants to support clinical and commercial plans. Management intends to use the facility to support ZUSDURI, advance next generation candidate UGN 103, and prepare for planned regulatory submissions. For context, UroGen Pharma focuses on urologic cancers, where recurrent non muscle invasive bladder cancer can require repeated procedures and carries meaningful quality of life implications. ZUSDURI and pipeline candidate UGN 103 are central to this effort, targeting patients who often cycle through limited options. The ENVISION data
Show less
Read more
Impact Snapshot
Event Time:
URGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
URGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
URGN
News
- UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers [Seeking Alpha]Seeking Alpha
- UroGen Pharma Ltd. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Urogen Pharma (URGN) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..MarketBeat
- UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
URGN
Earnings
- 3/2/26 - Beat
URGN
Analyst Actions
- 3/2/26 - Oppenheimer Holdings, Inc.
URGN
Sec Filings
- 3/2/26 - Form 10-K
- 3/2/26 - Form 8-K
- 3/2/26 - Form 8-K
- URGN's page on the SEC website